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Objective: To address the need for standardization of osteoarthritis (OA) phenotypes by examining the
effect of heterogeneity among symptomatic (SOA) and radiographic osteoarthritis (ROA) phenotypes.
Methods: Descriptions of OA phenotypes of the 28 studies involved in the TREAT-OA consortium were
collected. We investigated whether different OA deﬁnitions result in different association results by
creating various hip OA deﬁnitions in one large population based cohort (the Rotterdam Study I (RSI))
and testing those for association with gender, age and body mass index using one-way ANOVA. For ROA,
we standardized the hip-, knee- and hand ROA deﬁnitions and calculated prevalence’s of ROA before and
after standardization in nine cohort studies. This procedure could only be performed in cohort studies
and standardization of SOA deﬁnitions was not feasible at this moment.
Results: In this consortium, all studieswith SOAphenotypes (knee, hip and hand) used adifferent deﬁnition
and/or assessment of OA status. For knee-, hip- and hand ROAﬁve, four and sevendifferent deﬁnitionswere
used, respectively. Different hip ROA deﬁnitions do lead to different association results. For example, we
showed in the RSI that hip OA deﬁned as “at least deﬁnite joint space narrowing (JSN) and one deﬁnite
osteophyte”wasnot associatedwith gender (P¼ 0.22), but deﬁned as “at least one deﬁnite osteophyte”was
signiﬁcantly associated with gender (P¼ 3 109). Therefore, a standardization process was undertaken
for ROA deﬁnitions. Before standardization a wide range of ROA prevalence’s was observed in the nine
cohorts studied. After standardization the range in prevalence of knee- and hip ROAwas small.
Conclusion: Phenotype deﬁnitions inﬂuence the prevalence of OA and association with clinical variables.
ROA phenotypes within the TREAT-OA consortium were standardized to reduce heterogeneity and
improve power in future genetics studies.
 2010 Osteoarthritis Research Society International. Published by Elsevier Ltd.
Open access under the Elsevier OA license.Introduction
The Translational Research in Europe Applied Technologies for
OsteoArthritis (TREAT-OA) consortium was established in January
2008 to address the generalisability and utility of genetic and
biochemical risk factors (www.treatoa.eu). The two main goals of
TREAT-OA are (1) to develop efﬁcient diagnostics for risk and
progression of osteoarthritis (OA) and (2) to identify new targets for
therapeutic interventions. This will be done by identiﬁcation of
genes and biochemical markers consistently associatedwith risk and
progression of OA, but also by deﬁning the roles of these genes in
molecular pathways involved in disease aetiology, for example by
the development of in vivo transgenic animal OA model systems.
A major goal of the consortium is to identify new genes consis-
tently associated with risk and progression of OA. To reach this goal,
large-scale genome-wide association studies (GWASs) and meta-
analyses are being performed. To date, research within the TREAT-
OA consortium has resulted in the identiﬁcation of a novel genetic
locus on chromosome 7q22 that is associated with knee- and hand
OA1, which was conﬁrmed by a recently published GWAS meta-
analysis on knee OA2. In addition, the ataxin 2 binding protein 1
gene3 and the prostaglandin-endoperoxide synthase 2 gene4 have
been found associated with respectively hand- and knee OA.
Oneof thedifﬁculties in thesegeneticanalyses, andalso ingeneral in
epidemiological research of OA is heterogeneity of the deﬁnition of the
phenotype under study. Heterogeneity of the deﬁnition of the pheno-
type among different studies reduces power to ﬁnd consistent associ-
ations in any disease5. Two working groups of Human Genome
Epidemiology Network (HuGENet) and National Cancer Institute e
National Human Genome Research Institute (NCI-NHGRI) have
published recommendations for replication studies in genetic
epidemiology studies6e8. One of their recommendations was to try to
investigate the same or a very similar phenotype in replication studies.
Speciﬁcally for OA, the American College of Rheumatology (ACR)
criteria were developed to deﬁne clinical OA within a secondary care
setting9 and the OARSI-OMERACT initiative proposed deﬁnitions for
radiological progression of hip- and knee OA10. The problem of
heterogeneity in genetic association studies of OA has been high-
lighted11 and therefore standardized radiographic OA (ROA)phenotypes were used in our recent GWAS and subsequent meta-
analysis1. However, symptomatic OA (SOA) and ROA phenotypes were
both used within the same meta-analysis. For ROA, several grading
systems exists, but themostwidely and consistently used system is the
Kellgren and Lawrence (K/L) grading system12. Among major cohort
studies, K/L scores are interpreted differently, especially for the knee
and hip, despite the fact that they all refer to the original
description13e15.
In the current study, we have examined the effect of heteroge-
neity among SOA and ROA phenotypes on association analyses, to
address the need for standardization of OA phenotypes to enhance
power for future association studies. We further provide recom-
mendations for standardization of OA phenotypes.Subjects and methods
Study populations
We collected data for 28 studies currently involved in the
TREAT-OA consortium on the following nine items: (1) reference
article, (2) study design, (3) ethnic origin, (4) country of origin, (5)
joint site(s) studied, (6) ROA or SOA deﬁnition, (7) availability of age
and/or body mass index (BMI) data, (8) percentage of women in the
study and (9) availability of follow-up data. Table I describes the
characteristics of all studies evaluated. A short description of each
study is given in the Supplementary data.OA deﬁnitions
OA phenotypes can be categorized into SOA and ROA, and this
information was collected from all studies. Subsequently, we asked
for the exact OA deﬁnition used in that particular study. For
example, if a study used a K/L score and used the cut-off value
deﬁned by a summary grade of 2 or more to deﬁne OA cases, the
exact description of a K/L of 2 was requested (e.g., deﬁnite osteo-
phytes with possible joint space narrowing (JSN) vs deﬁnite
osteophyte(s) only) or a reference article was asked were the exact
interpretation of the K/L score was given.
Table I
Overview of all studies involved in the TREAT-OA consortium
Study Reference article Study design Ethnic origin Country of
origin
Joint site ROA/SOA Age/
BMI
% Women Follow-up
data
GWAS data
arcOGEN consortium Caseecontrol Caucasian United
Kingdom
Knee, hip ROA/SOA e 60% Not available
Chingford Study Hart and Spector36 Cohort Caucasian United
Kingdom
Knee, hip SOA þ 100% Available
Nottingham Casee
Control Study
Valdes et al.37 Caseecontrol Caucasian United
Kingdom
Knee, hip SOA þ 53% Not available
Oxford Study Chapman et al.38 Caseecontrol Caucasian United
Kingdom
Knee, hip SOA e 55% Not available
Shefﬁeld Study Gordon et al.39 Caseecontrol Caucasian United
Kingdom
Hip SOA þ* 53% Not available
TwinsUK Spector and
Williams40
Cohort Caucasian United
Kingdom
Knee, hip ROA þ 100% Available
VIDEO Not available yet RCT Caucasian United
Kingdom
Knee SOA þ 60% Available in
2011
Other
deCODE Ingvarsson41 and
Stefansson et al.42
Caseecontrol Caucasian Iceland Knee, hip, hand SOA þ* 58% Not available
Framingham
Osteoarthritis
Study
Hunter et al.43 Cohort Caucasian United
States
Knee, hand ROA þ 56% Available
GARP Riyazi et al.44 Cohort Caucasian Netherlands Knee, hip, hand SOA/ROA þ 65% Available
Health 2000 Kaila-Kangas45 Cohort Caucasian Finland Hip, knee SOA þ 55% Available
RSI Hofman et al.46 Cohort Caucasian Netherlands Knee, hip, hand ROA þ 59% Available
RSII Hofman et al.46 Cohort Caucasian Netherlands Knee, hip, hand ROA þ 56% Available
RSIII Hofman et al.46 Cohort Caucasian Netherlands Knee, hip, hand ROA þ 57% Available
in future
TwinsUK Spector and
Williams40
Cohort Caucasian United
Kingdom
Knee, hip, hand ROA þ 100% Available
De novo genotyping
Chingford Study Hart and Spector36 Cohort Caucasian United
Kingdom
Knee, hip, hand ROA þ 100% Available
Chinese Casee
Control Study
Miyamoto et al.47 Caseecontrol Asian China Knee SOA þy 75% Not available
D&T Study Solovieva et al.48 High risk cohort Caucasian Finland Hand ROA þ 100% Only symptoms
Estonian Studies Tamm et al.49 Cohort Caucasian Estonia Knee ROA þ 65% Available
Finnish OA cases Näkki et al.50 Caseecontrol Caucasian Finland Hand, knee SOA/ROA þ 76% Not available
Greek clinical cases Fytili et al.51 Caseecontrol Caucasian Greece Knee SOA þ 78% Not available
HCS Abdin-
Mohamed et al.17
Cohort Caucasian United
Kingdom
Knee, hand ROA þ 50% Availablez
Japanese Casee
Control Study
Miyamoto et al.47 Caseecontrol Asian Japan Knee, hip SOA þy 80% Not available
Japanese Cohort Study Miyamoto et al.47 Cohort Asian Japan Knee ROA þ 75% Availablex
KANON Frobell et al.52 High risk cohort Caucasian Sweden Knee ROA þ 26% Available in
2011
LUMEN Englund and
Lohmander18
High risk cohort Caucasian Sweden Knee ROA þ 21% Available
MDC study Lohmander et al.53 Cohort Caucasian Sweden Knee, hip SOA þ 65% Available
MrOS Orwoll et al.54 Cohort Caucasian United
States
Hip ROA þ 0% Available
Nottingham
CaseeControl
Valdes et al.37 Caseecontrol Caucasian United
Kingdom
Knee, hip SOA þ 53% Not available
Spanish clinical
cases
Rodriguez-
Lopez et al.55
Caseecontrol Caucasian Spain Knee, hip, hand SOA þ 65% Not available
SOF Nevitt et al.56 Cohort Caucasian United
States
Hip ROA þ 100% Available
The ROAD Study Muraki et al.57 Cohort Asian Japan Knee ROA þ 65% Available in
2010
GWAS ¼ genome-wide association study; ROA ¼ radiographic osteoarthritis; SOA ¼ symptomatic osteoarthritis; BMI ¼ body mass index; RCT ¼ randomized clinical trial;
GARP ¼ Genetics osteoARthritis and Progression; RS ¼ Rotterdam Study; D&T ¼ dentists & teachers; HCS ¼ Hertfordshire cohort study; MDC ¼ Malmö Diet and Cancer;
MrOS¼Osteoporotic Fractures inMen Study; ROAD¼ Research on Osteoarthritis/Osteoporosis Disability; SOF¼ Study of Osteoporotic Fractures; Age/BMIþ: age and BMI data
are available for all subjects; D&T¼ dentists & teachers; MDC¼Malmö Diet and Cancer.
* Age is available for all subjects, BMI only for part of the subjects.
y Only for the cases data on age and BMI is available.
z Available for clinical data, not available for X-ray data.
x For part of the subjects follow-up data is available.
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Within RSI radiographic features are scored separately for hip
OA (such as osteophytes, sclerosis and JSN at the lateral, superiorand axial site of the hip joint)16. In addition, total hip replacement
(THR) and the presence of pain during the last month are recorded.
To discover if differences in case deﬁnitions result in different
association results, we created all hip OA case deﬁnitions used by
Table IIa
Description of the radiographic knee OA deﬁnition according to 14 studies of the TREAT-OA consortium
Study Classiﬁcation
system
Cut-off value
for OA
Exact OA deﬁnition
Chingford Study K/L score 2 One deﬁnite osteophyte
Estonian Studies K/L score 2 Deﬁnite osteophytes
Finnish cases K/L score 3 Deﬁnite osteophytesþ deﬁnite JSN and/or joint deformation
Framingham Osteoarthritis Study K/L score 2 Deﬁnite osteophytes and possible JSN
GARP K/L score 2 Deﬁnite osteophytes and possible JSN
HCS K/L score 2 Deﬁnite osteophytes
Japanese Cohort Study K/L score 2 One deﬁnite osteophyte
KANON e e JSN grade2 or sum of two marginal osteophyte grades from the same
compartment2 or grade 1 JSNþ grade 1 osteophytes in the same compartment
LUMEN e e JSN grade2 or sum of two marginal osteophyte grades from the same
compartment2 or grade 1 JSNþ grade 1 osteophytes in the same compartment
RSI K/L score 2 Deﬁnite osteophytes and possible JSN
RSII K/L score 2 Deﬁnite osteophytes and possible JSN
RSIII K/L score 2 Deﬁnite osteophytes and possible JSN
The ROAD Study K/L score 2 One deﬁnite osteophyte
TwinsUK K/L score 2 One deﬁnite osteophyte
K/L ¼ Kellgren/Lawrence; JSN ¼ joint space narrowing; GARP ¼ Genetics osteoARthritis and Progression; RS ¼ Rotterdam Study; HCS ¼ Hertfordshire cohort study;
ROAD ¼ Research on Osteoarthritis/Osteoporosis Disability; e No standard classiﬁcation system is used to deﬁne OA.
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performed to study the relationship between different OA deﬁni-
tions of the hip and age, gender and BMI. One-way ANOVA was
used to assess the relationship between hip OA and the clinical
variables. The analyses were carried out using SPSS version 15.0.
Standardization of phenotypes
Consensus on which ROA phenotype to use within the TREAT-
OA consortium was based on the ROA deﬁnition as originally
described by K/L and the feasibility of its use within each of the
studies12. Total joint replacements (TJRs) due to primary OA
visible on radiographs are considered as OA. TJR due to fractures
and other diseases were excluded as much as possible. After
a consensus was reached between consortium members, the
cohort studies either shared their data with our research group
(RS) who standardized the deﬁnitions (data of TwinsUK, Ching-
ford Study) or performed the standardization process themselves
(other studies) if they were able and willing to standardize their
ROA deﬁnition. The prevalence of OA was calculated by dividing
the number of prevalent ROA cases over controls. Before stan-
dardization, controls were deﬁned as the absence of OA,
according to the deﬁnition used by each study, at the joint siteTable IIb
Description of the radiographic hand OA deﬁnition according to nine studies of the TREA
Study Classiﬁcation system Cut-off value
for OA
E
Chingford Study K/L score 2 
D&T Study Modiﬁed K/L score 2 
Finnish OA cases and families K/L score 2e3 K
Framingham Osteoarthritis Study K/L score 2 K
(
GARP K/L score 2 
HCS e e P
LUMEN e e P
o
s
c
RSI K/L score 2 T
TwinsUK K/L score 2 
K/L ¼ Kellgren/Lawrence; DIP ¼ distal interphalangeal joint; PIP ¼ proximal interph
MCP ¼ metacarpophalangeal joint; GARP ¼ Genetics osteoARthritis and Progression; RS
e No standard classiﬁcation system is used to deﬁne OA.
* Affected means K/L2 (¼deﬁnite osteophyte) in each or both hands.
y Affected means modiﬁed K/L2 (¼a single radiographic sign indicative of OA, slight to
degeneration cysts or slightmarginal sclerosis, eachof the latter signswithout a clear narrow
z Affected means K/L2 (¼deﬁnite osteophyte) irrespective of left or right hand.studied. After standardization, controls were deﬁned as the
absence of OA, according to the standardized deﬁnition as
described in the results section, at the joint site studied.
Results
Study populations
Since the start of the TREAT-OA consortium in 2008, the number
of teams collaborating with the consortium has grown to include 28
teams participating as of April 2010. The studies originate from
Europe, the United States of America and Asia. In 24 of the 28 studies
(86%), themajority of subjects included arewomen (63% on average).
With respect to genetic data, there are in total 11 studies with GWAS
data, two studies in which part of the subjects have GWAS data and
15 studies without GWAS data. A short description of all studies
involved in the consortium is given in the Supplementary data.
OA deﬁnitions
In total, there were 11 studies using a symptomatic deﬁnition of
OA and 15 studies with a radiographic deﬁnition. Two studies could
not be classiﬁed as completely SOA/ROA.T-OA consortium
xact OA deﬁnition
3 Joints (DIP/PIP/CMC1) affected*
2 Joints (DIP/PIP/MCP) affectedy
/L 3 for index cases and K/L2 for their siblings (DIP bilateral)
/L 2 (one deﬁnite osteophyte): joint speciﬁc deﬁnitions
i.e., DIP OA, PIP OA etcetera)
3 Joints (DIP/PIP/CMC1) affectedz
resence of Heberden’s or Bouchard’s nodes
resence of OA (JSN grade2 or osteophyte grade2 or JSN grade 1þ
steophyte grade 1) in at least one DIP or PIP joint in each hand
ymmetrically or at least one DIP/PIP joints in the same hand in a pattern
onsistent with primary OA (in the same row or ray) or the CMC1 joint bilaterally
wo out of three hand joint groups (DIP/PIP/CMC1 or TS) affected*
3 Joints (DIP/PIP/CMC1) affected*
alangeal joint; CMC1 ¼ ﬁrst carpometacarpal joint; TS ¼ trapezioscaphoid joint;
¼ Rotterdam Study; D&T ¼ dentists & teachers; HCS ¼ Hertfordshire cohort study
moderate lowering of the joint space, sometimes subluxation, minimal osteophytes,
ingof joint space but little if any additional pathology) irrespective of right or left hand.
Table IIc
Description of the radiographic hip OA deﬁnition according to seven studies of the
TREAT-OA consortium
Study Classiﬁcation
system
Cut-off
value for
OA
Exact OA deﬁnition
Chingford
Study
K/L score 2 Deﬁnite osteophyte
GARP Study K/L score 2 Deﬁnite JSNþ deﬁnite osteophyte
MrOS Modiﬁed
Croft grade
2 Presence of either deﬁnite JSN or
deﬁnite osteophytes plus at least
one of ﬁve other features: osteophytes,
JSN, sclerosis, cysts or femoral
head deformity
RSI K/L score 2 Deﬁnite JSNþ deﬁnite osteophyte
RSII K/L score 2 Deﬁnite JSNþ deﬁnite osteophyte
SOF Modiﬁed
Croft grade
2 Presence of either deﬁnite JSN or
deﬁnite osteophytes plus at least
one of ﬁve other features: osteophytes,
JSN, sclerosis, cysts or femoral
head deformity
TwinsUK Croft grade 1 Deﬁnite osteophytes
OA ¼ osteoarthritis; K/L ¼ Kellgren and Lawrence; JSN ¼ joint space narrowing;
GARP ¼ Genetics osteoARthritis and Progression; MrOS ¼ Osteoporotic Fractures in
Men Study; RSI ¼ Rotterdam Study-I; RSII ¼ Rotterdam study-II; RSIII ¼ Rotterdam
Study-III; SOF ¼ Study of Osteoporotic Fractures.
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For knee OA, there are 14 studies using radiographic deﬁni-
tions of knee OA shown in Table IIa with a detailed description of
the knee ROA deﬁnition. A total of 12 studies used the K/L score,
of which 11 studies used a cut-off value of 2 to deﬁne knee ROA
and one study used a more stringent cut-off of 3. Two studies,
which are both high risk cohorts, used a deﬁnition of OA not
according to a standard classiﬁcation system. As is shown in
Table IIa, four different interpretations are given for the K/L score
of the knee considering a cut-off value of 2 although all studies
used the original K/L atlas. In Tables IIb and c, results are given
for hand- and hip ROA respectively in a similar way as for knee
ROA.
For hand ROA, most studies (seven out of nine) used the K/L
score to deﬁne hand OA, with the exception of two studies16,17.Table IIIa
Description of the symptomatic knee OA deﬁnitions according to 10 studies of the TREA
Study OA deﬁnition based on Exact
Chinese CaseeControl Study K/L gradeþ symptoms K/L
over
septi
deCODE Hospital records of TJR TKR.
Greek clinical cases TJR due to OA reported by specialist TKRþ
Health 2000 Clinical records of OA or TKR Histo
knee
least
of th
not c
Japanese CaseeControl Study K/L gradeþ symptoms SOA
MDC Study Incident knee arthroplasty/osteotomy
from national Swedish hospital
discharge register
First
to th
Nottingham CaseeControl Clinically severe knee OA based on
hospital orthopaedic surgery lists
Refer
majo
Pre-o
Exclu
Oxford Study Severe symptomatic knee OAþ K/L grade Signs
deﬁn
Spanish clinical cases TJR TKR,
Exclu
patho
VIDEO K/L gradeþ pain K/L
OA ¼ osteoarthritis; TJR ¼ total joint replacement; TKR ¼ total knee replacement; JSN ¼The interpretation of this K/L score is the same for all these
studies, but there are four different hand ROA deﬁnitions based
on the number of joints included. For example, two studies deﬁne
OA in one hand joint as at least one deﬁnite osteophyte, but hand
OA is deﬁned as “3 joints (distal interphalangeal joint (DIP)/
proximal interphalangeal joint (PIP)/ﬁrst carpometacarpal joint
(CMC1)) affected” in one study and “2 out of 3 hand joint groups
(DIP/PIP/CMC1 or trapezioscaphoid joint (TS)) affected” in
another study.
Hip ROA was deﬁned by the (modiﬁed) Croft grade in three
studies and by the K/L score in four studies. Also for hip ROA there is
no consensus on the interpretation of the K/L score as two different
interpretations are present among the studies. This includes both
“deﬁnite JSN and a deﬁnite osteophyte” OR “one deﬁnite osteo-
phyte”. The Croft grade cut-off of 1 as a criterion for hip ROA, is
deﬁned as deﬁnite osteophytes and does not include JSN.
SOA
For knee OA, there are 10 studies using clinical deﬁnitions of knee
OA, which are shown in Table IIIa. In total, four of these 10 studies
deﬁned knee OA as ROAþ symptoms, but the inclusion of patients
was done in four different ways. For example, one study used a K/L
score  2 (deﬁned as one deﬁnite osteophyte)þmedial joint
space> 1 mmþ pain to include patients, whilst another study used
a K/L score 3þ SOA and treated on a regular basis. The other six
studies included patients on the basis of TJRs due to primary OA or
a combination of a TJR or ROA and clinical symptoms of OA.
In Tables IIIb and c, results are given for hand (n¼ 2) and hip
(n¼ 8) SOA respectively in a similar way as for SOA of the knee. Also,
these deﬁnitions differed for each study. In summary, hand SOAwas
deﬁned by either ACR criteria or by patient records. Hip SOA was
deﬁned as a THR by three studies although the assessment was
different for all three studies (i.e., based on hospital records vs based
on the description of a rheumatologist). In addition, two studies
deﬁned SOA of the hip as symptoms of OAþ ROA, but the deﬁnition
of ROA is unclear and inclusion based on symptoms differs.
Furthermore, there were three additional studies deﬁning hip SOA
again in another way (i.e., incident THR or either clinical records of
SOA or a THR).T-OA consortium
OA deﬁnition
2 (¼one deﬁnite osteophyte)þ pain with rest and/or night pain of
5-month duration. Exclusion of inﬂammatory, posttraumatic, post
c arthritis, dysplasias
A clinician reviewed the patients records to verify the diagnosis
K/L2 (¼deﬁnite osteophytesþ possible JSN)
ry, records and a standardized clinical diagnosis of previously diagnosed
OA or knee arthroplasty due to OA based on convincing ﬁndings OR at
moderately restricted mobility OR slightly restricted mobility and either
e following: documented history of previously diagnosed knee OA but
onvincingly presented grounds for the diagnosis or typical symptoms of knee OA
and treated on a regular basisþ K/L3
knee arthroplasty or high tibial osteotomyþ diagnosis of OA according
e International Classiﬁcation of Disease (ICD) 9 and 10
red to the hospital with symptomatic, clinically severe knee OA and the
rity had undergone unilateral or bilateral TKR within the previous 5 years.
perative knee radiographs were examined to conﬁrm the diagnosis.
sion based on another major arthropathy, Paget’s disease
and symptoms of OA sufﬁciently severe to require TKRþK/L2 (exact
ition unknown). Exclusion based on dysplasia
a rheumatologists considered patients to suffer from severe primary OA.
sion based on inﬂammatory, infectious, traumatic or congenital joint
logy and lesions due to crystal deposition or osteonecrosis
2 (¼one deﬁnite osteophyte)þmedial joint space width>1 mmþ knee pain
joint space narrowing; MDC ¼ Malmö Diet and Cancer.
Table IIIb
Description of the symptomatic hand OA deﬁnitions according to two studies of the
TREAT-OA consortium
Study OA deﬁnition
based on
Exact OA deﬁnition
deCODE Patients records at
hospitals and health
centres
Included on the basis of clinical
examination by an experienced
examiner, supported by a radiograph
for >60% of the cases
Spanish
clinical
cases
ACR criteria Patients were complaining of hand OA
and followed in the Rheumatology Unit.
The ACR criteria were used for inclusion
in the study
OA ¼ osteoarthritis; ACR ¼ American College of Rheumatology.
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In Table IV, association results are given for the relationship
between age, gender and BMI and different hip OA deﬁnitions.When
hip OA was deﬁned radiographically as “one deﬁnite osteophyte”
subjects with hip OA were more frequently men compared to
controls (mean difference of 10%, P¼ 3109), whilst subjects with
a THR were more frequently women compared to controls (mean
difference of 21%, P¼ 0.001). When ROA deﬁnitions were compared,
we observed that hip ROA deﬁned as “one deﬁnite osteophyte” were
more frequently men compared to controls (P¼ 3109), whilst hip
OA deﬁned as “deﬁnite JSN and one deﬁnite osteophyte” was not
associated with gender (P¼ 0.22). When analyzing SOA, we did not
observe clear differences in association results for the different
deﬁnitions of SOA, but the number of cases for SOA is much lower
than for ROA, therefore results should be taken with caution.Standardization of phenotypes
Consensus was reached for the knee- and hip OA deﬁnition based
on the ROA deﬁnition as originally described by K/L12 and at the
feasibility within each of the studies. It was agreed that the knee ROA
deﬁnition used within the TREAT-OA consortium is the original K/L
score12 deﬁned as “deﬁnite osteophytes and possible JSN” at the
tibio-femoral (TF) joint. If studies did not score possible JSN asTable IIIc
Description of the symptomatic hip OA deﬁnitions according to eight studies of the TREA
Study OA deﬁnition based on Exact O
deCODE Hospital records of TJR THR. A
Health 2000 Clinical records of OA or THR History
or hip
restrict
in exte
adduct
hip OA
Japanese CaseeControl Study Symptomsþ radiographs Subject
basisþ
MDC Study Incident hip arthroplasty from
national Swedish hospital
discharge register
First hi
accord
Nottingham CaseeControl Clinically severe hip OA based
on hospital orthopaedic surgery lists
Referre
had un
hip rad
major
trauma
Oxford Study Severe symptomatic hip OAþ K/L grade Signs a
unknow
Shefﬁeld Study THR Subject
radiogr
Spanish clinical cases TJR THR, a
based o
lesions
OA ¼ osteoarthritis; TJR ¼ total joint replacement; THR ¼ total hip replacement; MDC ¼a separate feature, the deﬁnition used was: “at least two deﬁnite
osteophytes OR one deﬁnite osteophyte plus deﬁnite JSN”. Hip ROA,
which was the most poorly speciﬁed in the original scores, was
deﬁned as “at least deﬁnite JSN”. For hand ROA, consensus was not
reached within the consortium, due to the fact that different studies
graded different joints for hand OA, thus limiting the possibility to
generate a single deﬁnition. As an alternative, thumb OA was put
forward as an interesting phenotype to study, because of the high
correlation with pain and disability19. Consensus was reached on
a deﬁnition for thumb OA which is “at least one deﬁnite osteophyte
(¼original K/L grade2) in either the left or right CMC1”.
In Table V, the number of cases and controls for each study are
given after standardization of phenotypes (both SOA and ROA). In
total, there are 13,119 knee OA cases and 61,538 controls, 9521 hipOA
cases and 59,345 controls and 4913 hand OA cases and 41,863
controls with DNA and phenotype data within the TREAT-OA
consortium.
To evaluate the effect of standardization of the ROA phenotypes,
we calculated the prevalence of knee- and hip ROA in eight
Caucasian and one Japanese cohort study before and after stan-
dardization of the ROA deﬁnition. In Table VI, the mean age and BMI
are shown for the nine cohorts. The Framingham Osteoarthritis
Study, The Hertfordshire Cohort Study (HCS), The Osteoporotic
Fractures in Men Study (MrOS), The RSI, the ROAD Study and the
Study of Osteoporotic Fractures (SOF) are on average 14 years older
than The Chingford Study, the RSIII and TwinsUK. The result of the
standardization of knee- and hip OA phenotypes is shown in Fig. 1.
Results for the thumb OA phenotype are not shown since all studies
use the same deﬁnition. The standardized hip OA deﬁnition is “at
least deﬁnite JSN or a THR visible on the radiograph due to primary
OA”. In the SOF and MrOS Study a minor adjustment was made and
hip ROA was deﬁned as: “at least medial JSN (grade3) or lateral
JSN (grade2) or a THR visible on the radiograph due to primary
OA”. The standardized knee ROA deﬁnition is “at least deﬁnite
osteophytes and possible JSN or a total knee replacement (TKR)
visible on the radiograph due to primary OA”.
Before standardization the prevalence of knee OA ranged
between 10% and 55%, of hip OA between 2% and 33%. After stan-
dardization the prevalence of knee OA ranged from 8% to 25% andT-OA consortium
A deﬁnition
clinician reviewed the patients records to verify the diagnosis
, records and a standardized clinical diagnosis of previously diagnosed hip OA
arthroplasty due to OA based on convincing ﬁndings OR at least moderate
ions in extension or in inner rotation or in outer rotation OR slight restrictions
nsion, inner rotation, outer rotation or at least moderately restricted abductione
ion and either of the following: documented history of previously diagnosed
but no grounds for the diagnosis is given or typical symptoms of hip OA
s are symptomatic and were treated in participating institutions on a regular
radiographic signs of hip OA (exact deﬁnition unknown)
p arthroplasty in combination with a contemporaneous diagnosis of hip OA
ing to the International Classiﬁcation of Disease (ICD) 9 and 10
d to the hospital with symptomatic, clinically severe hip OA and the majority
dergone unilateral or bilateral THR within the previous 5 years. Pre-operative
iographs were examined to conﬁrm the diagnosis. Exclusion based on another
arthropathy, Paget’s disease, overt child hip disease, THR due to
or terminal illness
nd symptoms of OA sufﬁciently severe to require THRþ K/L 2 (exact deﬁnition
n). Exclusion based on dysplasia
s had undergone THR for clinical, idiopathic OA that was conﬁrmed
aphically prior to joint replacement (exact radiographic deﬁnition uknown)
rheumatologists considered patients to suffer from severe primary OA. Exclusion
n inﬂammatory, infectious, traumatic or congenital joint pathology and
due to crystal deposition or osteonecrosis
Malmö Diet and Cancer.
Table IV
Association results of different hip OA case deﬁnitions (prevalence) and gender, age and BMI in the RSI
OA phenotype Number Gender (% women) Age (mean) BMI (mean)
Cases Controls Cases Controls P-value Cases Controls P-value Cases Controls P-value
ROA
Deﬁnite JSN and one deﬁnite
osteophyte (original K/L2)
242 3037 54% 58% 0.22 68.1 65.7 3 108 26.3 26.3 0.99
One deﬁnite osteophyte 1906 1373 54% 64% 3 109 66.1 65.5 0.009 26.2 26.4 0.07
SOA
THR 64 3215 78% 57% 0.001 71.2 65.7 8 1011 26.9 26.3 0.18
ROA (original K/L2)þ pain 58 3221 79% 57% 0.001 69.9 65.8 3 106 26.7 26.3 0.38
ROA (original K/L3)þ pain 23 3256 70% 58% 0.26 70.0 65.8 0.003 26.4 26.3 0.88
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same age range, the prevalence of knee ROA was 8e12% in the
younger cohorts and 16e25% in the cohorts with subjects of an older
age. To show that the differences in age are indeed the cause of theTable V
Number of cases (including incident cases) and controls in each study involved in
the TREAT-OA consortium according to standardized phenotypes
Study Knee OA Hip OA Thumb OA
Cases Controls Cases Controls Cases Controls
ROA
Chingford Study 80 560 34 702 356 620
D&T Study e e e e 36 507
Estonian Studies 70 441 e e e e
Framingham
Osteoarthritis Study
419 1674 e e 913 2783
HCS 156 831 e e 78 179
Japanese Cohort Study 226* 486 e e e e
KANON NA* NA e e e e
LUMEN 152* 317 e e 55 197
MrOS e e 389 3660 e e
RSI 1017y 2452 581y 3183 868z 2516
RSII NAy NA NAy NA NAy NA
RSIII 136 922 NAy NA e e
SOF e e 364 3668 e e
The ROAD Study 541 2,426 e e e e
TwinsUK 149 1436 105 1253 393 1565
Subtotal ROA 2946 11,545 1473 12,466 2699 8364
SOA/ROA
Finnish OA cases 113 210 e e ex ex
GARP 161 720 106 720 151 720
Subtotal SOA/ROA 274 930 106 720 151 720
SOA
Arcogen consortium 4287k 4287 4107k 4107 e e
Chinese CaseeControl
Study
1200k 1500 200 1500 e e
deCODE 1033 32,482 1571 32,482 1822 32,482
Greek clinical cases 228 344 67 344 e e
Health 2000 237 6048 132 6151 e e
Japanese CaseeControl
Study
900 3400 e e e e
MDC 471 471 551 551 e e
Nottingham
CaseeControl
1355k 237 1011k 730 e e
Spanish clinical cases 188 294 303 294 241{ 294
Subtotal SOA 9899 49,063 7942 46,159 2063 32,776
Total 13,119 61,538 9521 59,345 4913 41,863
NA ¼ not applicable.
* Number of cases and controls unstandardized.
y Complete dataset available summer 2010.
z Scoring of radiographs in progress, complete dataset available in 2011.
x Available in the near future.
k Recruitment in progress.
{ Hand OA according to ACR criteria, thumb OA deﬁnition not possible.lower prevalence of knee OA in three cohort studies, we studied the
prevalence of knee ROA in one relatively young and one old cohort
with awide age range, respectively TwinsUK and RSI. The prevalence
of knee ROA ranged from 10% to 15% in subjects aged 65 years and
younger. In subjects aged 65 years and older, the prevalence ranged
from 29% to 34% for the two studies.Discussion
A wide range of OA deﬁnitions were used in the 28 studies
participating in the TREAT-OA consortium. Since heterogeneity in
phenotype deﬁnitions will reduce power to ﬁnd consistent associ-
ations, ROA phenotypes were standardized within the consortium.
There are some research ﬁelds inwhich speciﬁc attention is given
to phenotype deﬁnitions. This mainly concerns studies in the ﬁeld of
neuroscience (i.e., bipolar disorder or schizophrenia)20 and obesity21.
In contrast, published research involving OA, osteoporosis and heart
disease does not usually discuss phenotype deﬁnitions. Our results
showed that OA deﬁnitions should be standardized since association
results differ when varying ROA and SOA deﬁnitions are used within
the same study. In addition, it was recently shown that the ability to
detect hip OA genetic associations is inﬂuenced by proper pheno-
typing22. We showed by standardizing of ROA phenotypes, that
similar ROA prevalence’s could be obtained.
For hip ROA, a distinction can be made between atrophic OA
(presence of JSN without osteophytes), hypertrophic OA (presence
of osteophytes without JSN) or a composite score (both JSN and
osteophytes)23. It is known that these different forms of hip ROA
have different risk factors24,25. In addition, atrophic OA shows to be
a more progressive form of OA than hypertroﬁc OA26. Since some
studies interpret a K/L score2 as one deﬁnite osteophyte, whereas
other studies interpret this as deﬁnite JSN and one deﬁnite osteo-
phyte, a difference in association results would be expected.
Although the standardized deﬁnition agreed upon by the consor-
tium is based on JSN (hip ROA¼ at least deﬁnite JSN, with or
without osteophytes), a majority of the subjects (78% and 80% in the
RSI and RSIII, respectively) have both JSN and osteophytes. This
deﬁnition can therefore also be seen as a composite score. Although
less often used than the composite score of hip ROA, hypertrophic
hip and atrophic hip ROA deﬁnitions should also be standardized.
We suggest using “presence of at least one deﬁnite osteophyte at
the femoral head without deﬁnite JSN” as preferred deﬁnition for
hypertroﬁc OA and “deﬁnite JSN without the presence of any
osteophytes at all locations” as atrophic OA which was also used in
a previous study by Javaid et al.23.
It was difﬁcult to reach consensus on the hand ROA deﬁnition,
since different studies scored different joints. To overcome this
problem, a subtype for clinically relevant OA was suggested within
the consortium: thumb OA, associated with pain and disability19,27,
will be used within the consortium. The deﬁnition of ROA of the
Table VI
Baseline characteristics of six cohort studies with ROA phenotypes involved in the
standardization process
Study Mean age (range) Mean BMI (range)
Chingford Study 54 (44e67) 26 (17e47)
Framingham Osteoarthritis Study 64 (29e93) 26 (14e54)
HCS 65 (59e71) 27 (17e48)
Osteoporotic Fracture in Men Study 77 (69e97) 27 (18e50)
ROAD Study 70 (23e94) 23 (13e37)
RSI 68 (55e94) 26 (15e59)
RSIII 57 (45e89) 28 (14e57)
SOF 71 (65e91) 27 (16e59)
TwinsUK 54 (37e76) 25 (15e51)
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CMC1 joint”.
We recommend for future studies on ROA to always specify
the exact OA deﬁnition. A statement such as “we deﬁned OA as
a K/L2” should be avoided or the interpretation of this K/L score
should be given.
Since all studies involved in the consortium deﬁned SOA differ-
ently, or at least assessed the OA status differently, it is likely that
heterogeneity is a problem in studies on SOA. Standardization of SOA
would in principle be possible if studies had pain, clinical assessment
data for study subjects, as well as radiographic grade for the index
joints, age, BMI, for both cases and controls. The design of some
studies is suchhowever that there is no radiographic characterization
for cases and controls, which is necessary if SOA would be deﬁned
based on both symptoms and radiographs, and only a diagnosis of TJR
for an indication of OA is present. These are extant studies and to
collect homogenous SOA studies would require a huge investment of
resources aswell as time. However, there remains a lack of consensus
and guidelines about how SOA should be assessed. For example, the
ACR deﬁnes signs of OA as stiffness <30min, crepitus, bony tender-
ness, bony enlargement, no palpable warmth and pain in or around
the joint. The presence of these traits in subjects over the age of 50
(preferably accompanied by radiographic evidence of OA) isFig. 1. Prevalence of knee- and hip OA before andcommonly used in the design of randomized clinical trials (RCTs)28.
But these criteria were developed in a clinic setting so the sensitivity
and speciﬁcity of a diagnosis based on these criteria in a community
or primary care settings, are as yet unknown.
Most of the SOA cases included in the TREAT-OA consortium
are TJR cases with a primary indication of OA. Although it is
possible to deﬁne TJR as the main clinical outcome representative
of severe symptomatic large joint OA in itself, as has been
proposed for RCTs29, this might not be the best option. Recent
studies on this topic have revealed considerable heterogeneity in
the radiographic severity, functional disability and pain suffered
by TJR candidates30. In addition, the pain and disability compo-
nents among subjects undergoing TJR are signiﬁcantly correlated
with risk factors that also impact on ROA such as BMI, age, sex,
whilst being poorly correlated with radiographic severity30,31.
Further, not all patients with severe SOA can or are willing to get
a TJR either because of lack of access to healthcare, or they may be
afraid of surgery, or have co-morbidities that make them ineligible
etcetera32. TJR patients are usually recruited in secondary care
settings and might in some instances represent a non-random
subset of severe SOA.
In summary, additional research is needed to reach consensus
for in- and exclusion criteria and deﬁnitions of clinical OA/SOA
studies. We suggest that more thought should be given to the
establishment of clear guidelines for future research using SOA
cohorts, as this would have implications not just for genetic studies,
but also for the assessment of biomarkers, imaging and interven-
tional studies.
GWASs and meta-analyses have been1,33 and will continue to be
performed within the TREAT-OA consortium in order to identify
genes consistently associated with risk and progression of OA.
Presently, there are few genes discovered for OA bymeans of GWAS,
and this may be explained by heterogeneity of phenotypes and the
limited sample size used in the discovery GWAS samples up to now.
For example, in a previous GWAS, ROA and SOA deﬁnitions were
used within one meta-analysis1. It has been shown before that ROAafter standardization of the ROA phenotypes.
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addition, we showed in this study that the association between SOA
and age, gender and BMI is different compared to ROA. Although
the sample size would decrease using stratiﬁcation methods, the
statistical power might increase if there is a reduction in the
heterogeneity in the phenotype deﬁnition. Therefore, we recom-
mend that for future GWASs additional work is needed to stan-
dardize or stratify on ROA and SOA.
Fortunately, in the TREAT-OA consortium studies on ROA have
access to the source material and individual features of ROA are
scored separately. This enables us to easily establish standardized
phenotypes across cohorts.
Additionally, other phenotypes or possible predictors such as
hypertrophic vs atrophic forms of OA, joint shape, Magnetic
Resonance Imaging (MRI) based features, severe ROA (K/L 3 vs K/
L¼ 0) or generalized OA may expand our deﬁnitions of the OA
phenotypes and may increase the number of consistent associa-
tions in genetic studies. However, consensus among OA epidemi-
ologist on OA phenotypes should be reached within the OA ﬁeld,
prior to the performance of these association studies.
In conclusion, standardization of ROA phenotypes was carried
out in the TREAT-OA consortium to reduce heterogeneity as much
as possible. Standardization of SOA phenotypes, although desirable,
was not possible due to the caseecontrol study design of the
studies. In the future, more precise OA phenotypes and stratiﬁca-
tion according to SOA and ROA phenotypes are highly
recommended.Recommendations1 Future studies on OA should always specify the exact OA deﬁnition.
A statement such as “we deﬁned OA as a K/L2” should be avoided or the
interpretation of this K/L score should be given.
2 The use of standardized ROA deﬁnitions is recommended in association
studies with knee ROA deﬁned as “at least two moderate deﬁnite
osteophytes and possible JSN at the TF joint”, hip ROA as “at least deﬁnite
JSN” and thumb ROA as “at least one moderate deﬁnite osteophyte at
the CMC1 joint”.
3 Atrophic hip ROA is suggested to be deﬁned as “deﬁnite JSN without
the presence of any osteophytes at all locations” and hypertrophic hip
ROA as “presence of at least one moderate deﬁnite osteophyte at the
femoral head without deﬁnite JSN”.
4 Consensus is needed on in- and exclusion criteria and phenotype
deﬁnitions of SOA studies. More thought should be given to the
establishment of clear guidelines for future research using
clinical OA cohorts.
5 For future GWASs additional work must be done to stratify on
age/BMI and especially ROA and SOA.
6 Expansion of OA phenotypes is not discouraged. Other phenotypes
such as joint shape, MRI based features, severe ROA (K/L3 vs K/L¼ 0)
or generalized SOA/ROA may expand our deﬁnitions of the OA phenotypes,
but consensus among OA epidemiologist on these new OA phenotypes
should be reached, prior to the performance of these association studies.Author contribution
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